Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&T Committees May Be Redefined By Medicare Regs

Executive Summary

The Medicare implementing regulations will have a profound impact on the operations of pharmacy and therapeutics committees, Medco Government Affairs Consultant Terry Latanich told the P&T Society's recent annual conference

You may also be interested in...



Medicare Part D Could Alleviate “Bias” In Formulary Decisions

The use of pharmacy & therapeutics committees under the Medicare Part D drug benefit will help alleviate the bias sometimes seen in managed care decision making, Formulary Resources consultant Peter Penna suggested during the National Association of Chain Drug Stores' Medicare Prescription Drugs and Reform Conference in Baltimore March 3

Medicare Part D Could Alleviate “Bias” In Formulary Decisions

The use of pharmacy & therapeutics committees under the Medicare Part D drug benefit will help alleviate the bias sometimes seen in managed care decision making, Formulary Resources consultant Peter Penna suggested during the National Association of Chain Drug Stores' Medicare Prescription Drugs and Reform Conference in Baltimore March 3

Medicare P&T Committees Can Consider Costs, But Only In Broad Context

Medicare prescription drug plan pharmacy & therapeutics committees must consider the overall economic impact of coverage decisions - not just pharmacy costs - if they use pharmacoeconomic data in their analyses, the Centers for Medicare & Medicaid Services states in its final rule implementing Title I of the Medicare Modernization Act

Related Content

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel